RAPT Therapeutics shares tumble by 48% after zelnecirnon …
3 days ago · RAPT has a market cap of $54.3m. RAPT announced plans to shelve the two Phase II clinical trials in May, three months after the clinical hold. The Phase IIa (NCT05935332) and Phase IIb trial ...
RAPT Therapeutics Reports Improved Q3 2024 Results
1 day ago · The company reported a net loss of $18.4 million for the third quarter of 2024, significantly lower than the $31.4 million reported in the same quarter of 2023. This improvement was driven by a ...
Rapt's share price sinks after shelving AD drug under FDA hold
3 days ago · Rapt’s stock had been riding high around the $25 mark in the opening weeks of the year before the clinical hold brought it crashing down. This morning’s announcement did further damage, wiping ...
RAPT Therapeutics: Strategic Shift to Next-Gen Compounds …
3 days ago · In a report released yesterday, Yanan Zhu from Wells Fargo maintained a Buy rating on RAPT Therapeutics (RAPT – Research Report), with a price target of $4.00. Yanan Zhu’s rating is based on ...
Rapt Therapeutics price target lowered to $4 from $17 at Wells
2 days ago · November 12, 2024 — 06:25 am EST. Written by TheFly for TipRanks ->. Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Rapt Therapeutics (RAPT) to $4 from $17 and keeps an ...
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
3 days ago · Third Quarter Ended September 30, 2024. Net loss for the third quarter of 2024 was $18.4 million, compared to $31.4 million for the third quarter of 2023. Research and development expenses for the ...
RAPT Therapeutics, Inc. (RAPT) Latest Stock News & Headlines …
Get the latest RAPT Therapeutics, Inc. (RAPT) stock news and headlines to help you in your trading and investing decisions.
RAPT Therapeutics, Inc. (RAPT) Stock Price, News, Quote
Find the latest RAPT Therapeutics, Inc. (RAPT) stock quote, history, news and other vital information to help you with your stock trading and investing.
Rapt Therapeutics Stops Development of Asthma, Atopic
3 days ago · Shares of Rapt fell about 49% in pre-market trading after announcing the news. Shares have already shed about 88% since the start of the year. Zelnecirnon is one of two lead candidates for Rapt.
Rapt Therapeutics model under review at Stifel after ... - Nasdaq
3 days ago · Stifel notes that the firm’s model is under review after Rapt Therapeutics (RAPT) disclosed this morning that they will discontinue development of RPT193, or zelnecirnon, after recent FDA ...